ADMA Biologics Company Profile (NASDAQ:ADMA)

About ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics logoADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADMA
  • CUSIP: N/A
  • Web:
  • Market Cap: $78.67 million
  • Outstanding Shares: 25,793,000
Average Prices:
  • 50 Day Moving Avg: $3.22
  • 200 Day Moving Avg: $3.60
  • 52 Week Range: $2.67 - $6.88
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.56
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $12.29 million
  • Price / Sales: 6.40
  • Book Value: $1.07 per share
  • Price / Book: 2.85
  • EBITDA: ($17,610,000.00)
  • Net Margins: -198.99%
  • Return on Equity: -791.24%
  • Return on Assets: -63.60%
  • Debt-to-Equity Ratio: 0.87%
  • Current Ratio: 2.83%
  • Quick Ratio: 1.99%
  • Average Volume: 35,920 shs.
  • Beta: 2.48
  • Short Ratio: 0.47

Frequently Asked Questions for ADMA Biologics (NASDAQ:ADMA)

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

How were ADMA Biologics' earnings last quarter?

ADMA Biologics Inc (NASDAQ:ADMA) released its earnings results on Friday, August, 11th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.29. The firm earned $3.40 million during the quarter, compared to analysts' expectations of $3.52 million. ADMA Biologics had a negative net margin of 198.99% and a negative return on equity of 791.24%. View ADMA Biologics' Earnings History.

When will ADMA Biologics make its next earnings announcement?

ADMA Biologics is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for ADMA Biologics.

Where is ADMA Biologics' stock going? Where will ADMA Biologics' stock price be in 2017?

1 analysts have issued twelve-month price objectives for ADMA Biologics' stock. Their predictions range from $13.00 to $13.00. On average, they anticipate ADMA Biologics' stock price to reach $13.00 in the next year. View Analyst Ratings for ADMA Biologics.

Who are some of ADMA Biologics' key competitors?

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the folowing people:

  • Steven A. Elms, Chairman of the Board
  • Adam S. Grossman, President, Chief Executive Officer, Director
  • Jerrold B. Grossman D.P.S, Vice Chairman of the Board
  • Brian Lenz, Chief Financial Officer
  • James Mond M.D., Ph.D., Chief Scientific and Medical Officer
  • Bernhard R. M. Ehmer, Director
  • Bryant E. Fong, Independent Director
  • Dov A. Goldstein M.D., Independent Director
  • Lawrence P. Guiheen, Independent Director
  • Eric I. Richman, Independent Director

How do I buy ADMA Biologics stock?

Shares of ADMA Biologics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ADMA Biologics' stock price today?

One share of ADMA Biologics stock can currently be purchased for approximately $3.05.

MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  111 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  172
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ADMA Biologics (NASDAQ:ADMA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.00 (326.23% upside)
Consensus Price Target History for ADMA Biologics (NASDAQ:ADMA)
Price Target History for ADMA Biologics (NASDAQ:ADMA)
Analysts' Ratings History for ADMA Biologics (NASDAQ:ADMA)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/28/2017Maxim GroupReiterated RatingBuy$13.00MediumView Rating Details
8/1/2016Raymond James Financial, Inc.DowngradeStrong-Buy -> Market PerformN/AView Rating Details
(Data available from 10/22/2015 forward)


Earnings History for ADMA Biologics (NASDAQ:ADMA)
Earnings by Quarter for ADMA Biologics (NASDAQ:ADMA)
Earnings History by Quarter for ADMA Biologics (NASDAQ ADMA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.43)N/AView Earnings Details
8/11/2017Q2 2017($0.26)($0.55)$3.52 million$3.40 millionViewN/AView Earnings Details
5/12/2017Q1 2017($0.28)($0.51)$3.35 million$2.63 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.42)($0.34)$2.32 million$2.94 millionViewN/AView Earnings Details
8/12/2016Q2($0.39)($0.50)$2.35 million$2.27 millionViewN/AView Earnings Details
5/13/2016Q1($0.37)($0.43)$2.48 million$2.12 millionViewN/AView Earnings Details
11/10/2015Q315($0.39)($0.48)$1.50 million$1.85 millionViewN/AView Earnings Details
8/11/2015Q215($0.32)($0.37)$1.50 million$1.30 millionViewN/AView Earnings Details
5/12/2015Q115($0.32)($0.37)$1.50 million$1.50 millionViewN/AView Earnings Details
3/9/2015Q4 2014($0.38)($0.38)$1.52 million$1.41 millionViewN/AView Earnings Details
11/10/2014Q3 2014($0.37)($0.36)$1.37 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ADMA Biologics (NASDAQ:ADMA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.30)($0.30)($0.30)
Q3 20171($0.64)($0.64)($0.64)
Q4 20171($0.63)($0.63)($0.63)
(Data provided by Zacks Investment Research)


Dividend History for ADMA Biologics (NASDAQ:ADMA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ADMA Biologics (NASDAQ:ADMA)
Insider Ownership Percentage: 60.44%
Institutional Ownership Percentage: 34.55%
Insider Trades by Quarter for ADMA Biologics (NASDAQ:ADMA)
Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)
Insider Trades by Quarter for ADMA Biologics (NASDAQ:ADMA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/3/2016Adam S GrossmanCEOBuy200,000$6.50$1,300,000.00View SEC Filing  
5/3/2016Brian LenzCFOBuy2,500$6.50$16,250.00View SEC Filing  
5/3/2016James MondCMOBuy770$6.50$5,005.00View SEC Filing  
5/3/2016Jerrold B GrossmanDirectorBuy45,769$6.50$297,498.50View SEC Filing  
12/8/2015Adam S. GrossmanCEOBuy500$9.00$4,500.00View SEC Filing  
12/7/2015Jerrold B GrossmanDirectorBuy500$9.01$4,505.00View SEC Filing  
12/2/2015Adam S GrossmanCEOBuy2,250$9.15$20,587.50View SEC Filing  
12/2/2015Brian LenzCFOBuy1,000$9.15$9,150.00View SEC Filing  
12/2/2015Jerrold B GrossmanDirectorBuy6,000$9.16$54,960.00View SEC Filing  
12/1/2015Adam S GrossmanCEOBuy1,800$9.17$16,506.00View SEC Filing  
11/25/2015Adam S GrossmanCEOBuy1,800$9.18$16,524.00View SEC Filing  
11/20/2015Adam S GrossmanCEOBuy3,861$9.21$35,559.81View SEC Filing  
3/19/2015Adam S GrossmanCEOBuy2,000$8.50$17,000.00View SEC Filing  
3/17/2015Adam S GrossmanCEOBuy5,500$7.98$43,890.00View SEC Filing  
3/17/2015Jerrold B GrossmanDirectorBuy500$8.01$4,005.00View SEC Filing  
3/16/2015Adam S GrossmanCEOBuy8,800$8.03$70,664.00View SEC Filing  
3/16/2015James MondCMOBuy1,250$8.02$10,025.00View SEC Filing  
3/16/2015Lawrence P GuiheenDirectorBuy1,000$7.96$7,960.00View SEC Filing  
3/13/2015Eric I RichmanDirectorBuy3,500$7.88$27,580.00View SEC Filing  
9/12/2014Adam S GrossmanCEOBuy4,300$9.57$41,151.00View SEC Filing  
8/22/2014Adam S GrossmanCEOBuy1,000$9.50$9,500.00View SEC Filing  
8/14/2014Adam S GrossmanCEOBuy2,100$9.77$20,517.00View SEC Filing  
6/18/2014Adam S GrossmanCEOBuy1,875$9.59$17,981.25View SEC Filing  
5/22/2014Adam S GrossmanCEOBuy4,226$8.15$34,441.90View SEC Filing  
5/15/2014Adam S GrossmanCEOBuy13,400$7.50$100,500.00View SEC Filing  
5/14/2014Brian LenzCFOBuy1,000$7.50$7,500.00View SEC Filing  
5/14/2014James MondCMOBuy1,315$7.60$9,994.00View SEC Filing  
12/10/2013Jerrold B GrossmanDirectorBuy3,650$7.30$26,645.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ADMA Biologics (NASDAQ:ADMA)
Latest Headlines for ADMA Biologics (NASDAQ:ADMA)
Loading headlines, please wait.



ADMA Biologics (ADMA) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.